Receipt date: 03/25/2010 10650326 - GAU: 1649

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OM8 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/B/PTO			Complete if Known	
700000				Application Number	10/650,326
	VFORMATION	l Di	SCLOSURE	Filing Date	August 28, 2003
S	STATEMENT BY APPLICANT			First Named Inventor	Keith A. Hruska
***************************************				Art Unit	1649
7	(Use as many sheets as necessary)			Examiner Name	Christina M. Borgeest
Sheet	1	of	1	Attorney Docket Number	STK-P01-599

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
			L	Watanabe et al.	- garder spread	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code <sup>s</sup> -Number <sup>s</sup> -Kind Code <sup>s</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Retevant Passages or Relevant Figures Appear	Τö
		WO97/41881	11-13-1997	Creative Biomolecules, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.org/www.nsukw.org/www.nsukw.org/www.nsukw.org/www.org/www.nsukw.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.org/www.o

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	<b>T</b> 2		
		TAKODORO et al., The effect of low-dose ACE inhibitor (ACEI) on exacerbation of conservation stage with renal insufficiency, J. Japanese Society of Nephrology, 44(3):224 (2002)			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		***************************************
Evaminar	(Mariatina Danna anti /AF/AF/AAA)	Data
Examine:	/i .nrigiina Karaaagi/ iiih/iih//ziiiiii	Date
I Characterist I	/ VIII I3 III I4 DOTACCSI/ 100/00/2010/	On a side and 1
Signature (		Considered

<sup>1</sup>Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.